SIBO Treatment: Small Intestinal Bacterial Overgrowth Protocol

Quick answer: SIBO (small intestinal bacterial overgrowth) is defined as greater than 10³ colony-forming units per mL of bacteria in the small intestine, compared to the normal less than 10³ CFU/mL. It produces bloating, gas, abdominal pain, diarrhea or constipation, and nutritional malabsorption through bacterial fermentation of carbohydrates before absorption is complete. Three SIBO subtypes exist — hydrogen-dominant, methane-dominant (now termed IMO, intestinal methanogen overgrowth), and hydrogen sulfide — each requiring different treatment approaches. The root cause is always a breakdown in the small intestine’s clearance mechanisms: the migrating motor complex (MMC), ileocecal valve function, and stomach acid. Treating without addressing root cause produces recurrence in 40–50% of cases within 3 months.

What Is SIBO and Why It Matters

The small intestine is normally a relatively sterile environment — bacteria are present but in small numbers (below 10³ CFU/mL) because the small intestine is not designed for microbial fermentation. That work is reserved for the colon, where bacterial populations reach 10¹² CFU/mL and fiber fermentation to short-chain fatty acids is healthy and beneficial. SIBO occurs when bacteria — either ascending from the colon or proliferating from the small intestine’s own sparse population — colonize the small bowel in numbers that disrupt normal digestion and absorption.

The consequences of bacterial overgrowth in the small intestine are multiple: bacteria ferment carbohydrates (particularly FODMAPs — fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) before these sugars can be absorbed, producing hydrogen, methane, or hydrogen sulfide gas that causes bloating, distension, and pain. Bacteria compete for and consume vitamin B12, producing B12 deficiency. They deconjugate bile acids (required for fat absorption), impairing fat and fat-soluble vitamin (A, D, E, K) absorption. They damage the brush border of enterocytes, reducing digestive enzyme production. The net result is a syndrome of malabsorption, nutrient deficiency, and gut motility disruption that affects every downstream organ system.

The Three SIBO Subtypes

Hydrogen-dominant SIBO: The most common subtype. Characterized by bloating, gas, and diarrhea-predominant bowel habits. Hydrogen gas (H₂) produced by bacterial fermentation causes loose, urgent, or watery stools in many patients. On lactulose breath test, hydrogen rises above 20 ppm above baseline within 90 minutes. Associated organisms include Escherichia coli, Klebsiella, Enterococcus, and other facultative anaerobes. Treatment: rifaximin 550 mg three times daily for 14 days (the most studied antibiotic for SIBO, with 50–80% eradication rates across multiple trials) or herbal antimicrobials.

Methane-dominant SIBO (IMO — intestinal methanogen overgrowth): Methane gas is produced not by bacteria but by archaea — specifically Methanobrevibacter smithii — using hydrogen as a substrate. IMO is characterized by constipation (methane directly slows intestinal transit by activating µ-opioid receptors in enteric neurons), bloating, and harder, slower stools. On breath testing, methane rises above 10 ppm at any point in the test. Treatment requires a combination approach because rifaximin alone has poor activity against archaea: rifaximin 550 mg + neomycin 500 mg three times daily for 14 days achieves 87% methane reduction in the most cited trial. Herbal alternative: allicin (Allimed 450 mg three times daily) + berberine.

Hydrogen sulfide SIBO: The newest recognized subtype, producing the rotten egg odor associated with some patients’ gas. H₂S is produced by sulfate-reducing bacteria (Desulfovibrio, Fusobacterium) from sulfur-containing foods (meat, eggs, cruciferous vegetables, onions). Clinical features include diarrhea, abdominal pain that worsens with sulfur-containing foods, and in severe cases, neurological symptoms (H₂S is mitochondrial complex IV inhibitor). Standard lactulose breath tests do not measure H₂S — specialized 3-gas testing is required. Treatment: bismuth subsalicylate (Pepto-Bismol) 2 tablets four times daily for 4 weeks (bismuth binds hydrogen sulfide) combined with low-sulfur dietary modification and elemental diet if severe.

Root Causes: Why the Small Intestine Loses Bacterial Control

The small intestine has three primary defense mechanisms against bacterial overgrowth. Understanding these is essential for preventing SIBO recurrence after treatment:

The Migrating Motor Complex (MMC): The MMC is the “housekeeper” of the small intestine — a wave of powerful contractions (phase 3 contractions) that sweep through the small bowel every 90–120 minutes between meals, clearing bacteria and food debris toward the colon. This only occurs during fasting — eating interrupts the MMC immediately. MMC dysfunction is the most common predisposing cause of SIBO. Causes of MMC dysfunction: hypothyroidism (thyroid hormone is required for normal enteric nervous system function), diabetes neuropathy (autonomic neuropathy impairs vagal MMC regulation), opioid medications (opioids strongly suppress MMC), scleroderma, post-infectious dysmotility (the most common acquired MMC dysfunction — Campylobacter, Salmonella, and other bacterial infections produce autoimmune damage to the ICC — interstitial cells of Cajal — via anti-CdtB/anti-vinculin antibodies), and excessive meal frequency (no fasting intervals means no MMC cycles).

Stomach acid: Gastric acid kills the majority of bacteria before they reach the small intestine. PPI use — the most widely prescribed drug class in the U.S. — suppresses gastric acid and dramatically increases SIBO risk: meta-analysis shows PPI users have 7.6× greater odds of SIBO compared to non-users. This makes untreated SIBO diagnosis essential in any patient on long-term PPI therapy. Low stomach acid from any cause — whether medication, autoimmune gastritis, or H. pylori infection — removes a key bacterial defense layer.

Ileocecal valve competence: The ileocecal valve physically prevents retrograde migration of colonic bacteria into the small intestine. Ileocecal valve dysfunction (from previous abdominal surgery, adhesions, inflammatory bowel disease, or functional disturbance) allows the enormous colonic bacterial population to ascend and colonize the small bowel. Addressing structural ileocecal valve issues requires manual therapy or in severe cases surgical correction — though most ileocecal valve dysfunction is functional and responds to MMC restoration.

SIBO Diagnosis: Breath Testing

Lactulose or glucose breath testing is the standard non-invasive diagnostic for SIBO, though sensitivity and specificity are imperfect. The test: after a 24-hour low-fermentation preparation diet and 12-hour fast, the patient drinks either lactulose (a non-absorbable sugar that ferments throughout the GI tract) or glucose (absorbed in the small intestine — only small bowel bacteria can ferment it before it is absorbed). Breath samples are collected every 15–20 minutes for 2–3 hours and measured for hydrogen, methane, and ideally hydrogen sulfide.

Diagnostic criteria vary by lab, but the most widely accepted are: hydrogen peak above 20 ppm above baseline at any point within 90 minutes of lactulose ingestion (positive for hydrogen SIBO), or methane above 10 ppm at any point (positive for IMO). Glucose breath testing has higher specificity (fewer false positives) but misses distal small bowel SIBO where glucose absorption is complete before reaching the bacterial colony. For complete SIBO evaluation, lactulose 3-gas testing (H₂, CH₄, and H₂S simultaneously) is the most comprehensive option and is now offered by major functional medicine labs.

The SIBO Treatment Protocol

Phase 1: Antimicrobial Treatment

The antimicrobial phase targets the bacterial overgrowth directly. Options include:

Pharmaceutical antibiotics: Rifaximin is the gold standard — a non-systemic antibiotic that stays in the GI tract with no systemic absorption, minimizing microbiome disruption outside the small intestine. For hydrogen SIBO: rifaximin 550 mg three times daily × 14 days (response rate 50–80%). For methane/IMO: rifaximin 550 mg + neomycin 500 mg three times daily × 14 days (methane eradication rate 87% in one trial). Rifaximin is expensive without insurance; neomycin is inexpensive but has ototoxicity risk with long-term use — 14-day courses are generally safe.

Herbal antimicrobials: A 2014 Annals of Gastroenterology trial found herbal antimicrobials (FC-Cidal/Dysbiocide — berberine and other botanicals) produced equivalent eradication rates to rifaximin for hydrogen SIBO (46% vs. 34% normalization, p=ns). Herbal protocols are appropriate for patients who cannot access or tolerate rifaximin. Berberine at 1,500 mg/day has documented antimicrobial, anti-biofilm, and motility-enhancing properties. Common herbal SIBO protocols: oregano oil (200 mg twice daily), berberine (500 mg three times daily), allicin (Allimed 450 mg three times daily for methane), and neem — used in combination for 4–6 weeks.

Elemental diet: A 2-week elemental diet (amino acid-based, no intact protein or carbohydrate that bacteria can ferment) starves bacteria while providing complete nutrition to the host. The Pimentel protocol: 2 weeks of elemental formula as sole nutrition produces 80% hydrogen normalization — the highest eradication rate of any single intervention. Elemental diet is most appropriate for severe, refractory SIBO or in preparation for antibiotic treatment in very high-methane patients. Cost and palatability are the primary barriers.

Phase 2: Dietary Support During Treatment

Diet during antimicrobial treatment is debated — “starving the bacteria” by restricting FODMAPs reduces symptoms but may also reduce the die-off reaction that signals treatment efficacy. The pragmatic approach: low-FODMAP diet during treatment to reduce symptom burden, combined with adequate protein and fat intake to maintain nutrition and support gut repair. Avoid: fructose (fruit juice, high-fructose corn syrup), lactose (dairy), excess fructans (wheat, onions, garlic), and polyols (sugar alcohols in “sugar-free” products). These are the primary fermentation substrates that fuel bacterial gas production.

Phase 3: Root Cause Correction and Relapse Prevention

This is the most critical and most neglected phase — without addressing the predisposing cause, SIBO recurrence rates reach 40–50% within 3–12 months. Root cause correction strategies:

Prokinetics to restore MMC: Post-antibiotic prokinetic therapy is the single most evidence-backed relapse prevention strategy. Prokinetics stimulate phase 3 MMC contractions between meals. Options: low-dose naltrexone (LDN, 1.5–4.5 mg at bedtime) — the most commonly used functional medicine prokinetic, modulating opioid receptors and motilin release; ginger extract (IBgard or 550 mg ginger root three times daily before meals); Iberogast (9-herb German GI formula with strongest prokinetic evidence); 5-HTP (25–50 mg before bed, acts on 5-HT4 receptors in the enteric nervous system). Pharmaceutical options include low-dose erythromycin (50 mg twice daily at bedtime) and prucalopride.

Meal spacing: The MMC requires 3–5 hours of fasting to complete a cycle. Snacking continuously prevents the MMC from ever completing — maintaining bacterial overgrowth indefinitely regardless of antibiotic treatment. Spacing meals 4–5 hours apart with nothing between (water only) is essential for MMC restoration. Intermittent fasting protocols with a 12–16 hour overnight fast provide an additional extended MMC cycle during sleep.

Thyroid and blood sugar optimization: Hypothyroidism is a correctable cause of MMC dysfunction that is frequently missed. TSH above 2.5 impairs enteric nervous system function. Insulin resistance and elevated blood sugar impair autonomic nerve function (including the vagus nerve that regulates the MMC) — SIBO is dramatically more common in diabetes and pre-diabetes, and blood sugar normalization is required to maintain MMC function long-term.

Post-infectious SIBO — anti-vinculin antibody testing: When SIBO develops after a GI infection (food poisoning), the underlying mechanism is autoimmune — CdtB toxin from the infecting organism triggers antibodies that cross-react with vinculin (a protein in enteric nerve cells), damaging the ICC and MMC. Testing for anti-CdtB and anti-vinculin antibodies (iBS Smart test, Gemelli Biotech) confirms this mechanism and identifies patients who may benefit from interventions targeting autoimmunity alongside prokinetics.

SIBO and Its Connections to Other Conditions

SIBO is not an isolated gut condition — it drives and is driven by dysfunction across multiple body systems. Key connections: Hashimoto’s and hypothyroidism — the most common autoimmune thyroid disease is associated with SIBO in 54% of cases in one series, likely due to both MMC dysmotility and shared gut permeability drivers. Fibromyalgia — approximately 100% of fibromyalgia patients tested positive for SIBO in a landmark Pimentel trial, suggesting SIBO-driven neuroinflammation as a mechanism for central sensitization. Rosacea — H₂-producing bacteria produce acetaldehyde that triggers mast cell histamine release in skin (the SIBO-rosacea connection is confirmed by rifaximin treatment producing skin improvement). Restless legs syndrome — SIBO drives iron deficiency through competition and malabsorption, which drives RLS. Addressing SIBO is essential for complete iron repletion in SIBO patients.

The Bottom Line

SIBO is a structural and functional diagnosis that explains a wide range of digestive and systemic symptoms. The three subtypes — hydrogen, methane (IMO), and hydrogen sulfide — require different antimicrobial approaches. Treatment without root cause correction fails in nearly half of patients within one year. The complete protocol — accurate subtype diagnosis via 3-gas breath testing, subtype-specific antimicrobial treatment (rifaximin ± neomycin, or herbal protocol), post-treatment prokinetics, 4–5 hour meal spacing, and elimination of predisposing factors (PPI overuse, thyroid dysfunction, blood sugar dysregulation) — achieves durable remission in the majority of cases.

If you have chronic bloating, alternating bowel habits, unexplained nutritional deficiencies, or IBS that has not responded to dietary measures, a comprehensive SIBO evaluation including 3-gas breath testing is the appropriate next step. Call our office at (810) 206-1402 to schedule a functional medicine consultation with complete GI assessment and SIBO testing.

Frequently Asked Questions

What are the symptoms of SIBO?
The hallmark symptoms are bloating (particularly within 1-2 hours of eating carbohydrates), abdominal distension, excess gas, and altered bowel habits — diarrhea in hydrogen-dominant SIBO and constipation in methane-dominant SIBO (IMO). Additional symptoms include abdominal pain or cramping, nausea, early satiety, and nutritional deficiency symptoms (fatigue from B12 malabsorption, fat-soluble vitamin deficiency, iron deficiency). Systemic symptoms driven by SIBO include rosacea, brain fog, joint pain, histamine intolerance, and restless legs — all driven by the inflammatory and nutritional consequences of bacterial overgrowth in the small bowel.

How is SIBO diagnosed?
The standard non-invasive test is lactulose or glucose breath testing, measuring hydrogen, methane, and ideally hydrogen sulfide gas production over 2-3 hours. Positive criteria: hydrogen above 20 ppm above baseline within 90 minutes (hydrogen SIBO), or methane above 10 ppm at any point (IMO). Three-gas testing (H2+CH4+H2S simultaneously) is the most comprehensive option. The preparation diet (low fermentation for 24 hours before testing) and 12-hour fast are critical for accurate results. Small intestinal aspirate and culture is the gold standard but invasive and not practical for routine testing.

What is the best treatment for SIBO?
Treatment depends on the subtype. Hydrogen SIBO: rifaximin 550 mg three times daily for 14 days (50-80% eradication) or herbal antimicrobials (berberine, oregano, allicin) for 4-6 weeks with equivalent efficacy. Methane SIBO/IMO: rifaximin + neomycin combination for 14 days (87% methane reduction). Hydrogen sulfide: bismuth subsalicylate (4 tablets 4x daily) + low-sulfur diet. After any antimicrobial course, prokinetics (LDN, ginger, Iberogast) are essential for relapse prevention — addressing the MMC dysfunction that allowed SIBO to develop in the first place.

Does SIBO go away on its own?
SIBO rarely resolves without treatment. The conditions that allow it to persist — MMC dysfunction, low stomach acid, PPI use, poor meal spacing, thyroid dysfunction — continue to promote bacterial overgrowth unless addressed. Some patients experience partial symptom improvement with dietary restriction (low-FODMAP, low-carbohydrate) because reducing fermentable substrate reduces gas production — but the bacterial overgrowth itself persists and continues to damage the brush border, compete for nutrients, and drive systemic inflammation. Treatment to eradication followed by root cause correction and prokinetic therapy is required for durable resolution.

SIBO: Symptoms, Testing, and the Complete Treatment Protocol